01/12/2018

The FDA approved LYNPARZA® (olaparib) germline BRCA-mutated metastatic breast cancer

LYNPARZA is the first and only PARP inhibitor approved for use beyond ovarian cancer

LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy

The FDA has approved LYNPARZA^® (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for therapy based on an FDA-approved companion diagnostic from Myriad Genetics.

For more information, click here.